Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 77.7% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,442 shares of the company's stock after selling 29,346 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Astrana Health were worth $262,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Astrana Health by 136.1% in the fourth quarter. JPMorgan Chase & Co. now owns 163,532 shares of the company's stock valued at $5,156,000 after acquiring an additional 94,268 shares in the last quarter. Two Sigma Investments LP acquired a new position in Astrana Health in the 4th quarter valued at approximately $466,000. Wells Fargo & Company MN increased its stake in Astrana Health by 41.5% in the 4th quarter. Wells Fargo & Company MN now owns 22,484 shares of the company's stock valued at $709,000 after buying an additional 6,596 shares during the period. Dimensional Fund Advisors LP increased its stake in Astrana Health by 10.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,045,540 shares of the company's stock valued at $32,968,000 after buying an additional 101,192 shares during the period. Finally, First Trust Advisors LP increased its stake in Astrana Health by 702.6% in the 4th quarter. First Trust Advisors LP now owns 107,343 shares of the company's stock valued at $3,385,000 after buying an additional 93,969 shares during the period. Institutional investors own 52.77% of the company's stock.
Astrana Health Stock Up 1.4%
Shares of ASTH traded up $0.41 during mid-day trading on Tuesday, hitting $29.10. 503,631 shares of the company's stock were exchanged, compared to its average volume of 474,348. The firm has a fifty day moving average of $24.60 and a two-hundred day moving average of $29.02. Astrana Health, Inc. has a twelve month low of $21.20 and a twelve month high of $63.20. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of 56.26, a P/E/G ratio of 0.61 and a beta of 0.85. The company has a quick ratio of 1.59, a current ratio of 1.59 and a debt-to-equity ratio of 0.52.
Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.36 by ($0.17). Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. The firm had revenue of $654.81 million during the quarter, compared to analyst estimates of $639.13 million. During the same quarter in the previous year, the business posted $0.40 earnings per share. The business's quarterly revenue was up 34.7% compared to the same quarter last year. On average, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Read More

Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.